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ISSNBackground: Monitoring of HIV viral load in patients on combination antiretroviral
therapy (ART) is not generally available in resource-limited settings. We examined the
cost-effectiveness of qualitative point-of-care viral load tests (POC-VL) in sub-Saharan
Africa.
Design: Mathematical model based on longitudinal data from the Gugulethu and
Khayelitsha township ART programmes in Cape Town, South Africa.
Methods: Cohorts of patients on ART monitored by POC-VL, CD4 cell count or
clinically were simulated. Scenario A considered the more accurate detection of
treatment failure with POC-VL only, and scenario B also considered the effect on
HIV transmission. Scenario C further assumed that the risk of virologic failure is
halved with POC-VL due to improved adherence. We estimated the change in costs
per quality-adjusted life-year gained (incremental cost-effectiveness ratios, ICERs) of
POC-VL compared with CD4 and clinical monitoring.
Results: POC-VL tests with detection limits less than 1000 copies/ml increased costs
due to unnecessary switches to second-line ART, without improving survival. Assuming
POC-VL unit costs between US$5 and US$20 and detection limits between 1000 and
10 000 copies/ml, the ICER of POC-VL was US$4010–US$9230 compared with clinical
and US$5960–US$25540 compared with CD4 cell count monitoring. In Scenario B,
the corresponding ICERs were US$2450–US$5830 and US$2230–US$10380.
In Scenario C, the ICER ranged between US$960 and US$2500 compared with clinical
monitoring and between cost-saving and US$2460 compared with CD4 monitoring.
Conclusion: The cost-effectiveness of POC-VL for monitoring ART is improved by a
higher detection limit, by taking the reduction in new HIV infections into account and
assuming that failure of first-line ART is reduced due to targeted adherence counselling.
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Despite the rapid scale-up of combination antiretroviral
therapy (ART) in HIV-infected patients during the past
decade, the capacity to monitor treatment response remains
limited in many settings [1]. Routine viral load monitoring
is standard to detect virologic failure and inform decisions
on switching patients to second-line ART in industrialized
countries. In contrast, in most resource-limited settings,
these decisions are based on clinical symptoms and CD4
cell counts, which correlate poorly with viral load [2].
The main barriers for the implementation of viral load
monitoring in low-income settings are the need for
centralized laboratory facilities [3] and the required scale-up
of expensive second-line ART [4].
A recent randomized controlled trial (RCT) evaluating
the effect of routine laboratory monitoring on clinical
outcomes among patients on ART in Uganda showed that
compared with clinical monitoring alone, outcomes were
more favourable with laboratory monitoring, but there was
no significant difference between the CD4 arm and the
viral load arm [5]. The setting of an RCT may not,
however, reflect routine care in settings without access to
viral load monitoring, in which patients may stay on failing
first-line regimens for prolonged periods of time, which
may increase the risk of onward transmission of HIV [6],
lead to multidrug resistance [7] and increase mortality [8].
Lack of viral load monitoring hampers the detection of
poor adherence to ART and the targeted counselling of
patients [9]. Finally, a substantial number of patients may
switch unnecessarily with suppressed viral load [10].
In sub-SaharanAfrica, only SouthAfrica [11] andBotswana
[12] have implemented viral load monitoring in their
national ART programmes. Point-of-care (POC) tests are
being developed for monitoring both CD4 cell counts and
viral load. UNITAID and the Bill & Melinda Gates
Foundation are supporting the development and imple-
mentation of POC tests [13,14]. POC testing can improve
the monitoring of ART by making results available rapidly
and providing access to clinics in remote settings [13].
The aim of our study was to explore the cost-effectiveness
of routine POC-VL monitoring in settings in sub-Saharan
Africa where only CD4 cell count or clinical monitoring is
currently available. We assumed that the viral load test
would be qualitative and available to all patients on ART.
Wevaried the assumptions regarding the costs and detection
limits of the test, and the costs of second-line therapy.Materials and methods
Data sources
The International epidemiologic Databases to Evaluate
AIDS in Southern Africa (IeDEA-SA) is a collaborationpyright © Lippincott Williams & Wilkins. Unauthoof ART programmes in seven countries in Southern
Africa [15]. Data are collected at ART initiation (baseline)
and each follow-up visit using standardized instruments.
All sites have ethical approval to collect data and
participate in IeDEA-SA. We restricted our analyses to
the Gugulethu [16] and Khayelitsha [17] township ART
programmes in Cape Town, South Africa, where viral
load and CD4 cell counts are measured regularly
(Table 1). All treatment-naive patients aged at least
16 years, who had started ART with at least two
nucleoside reverse transcriptase inhibitors (NRTIs) and
one nonnucleoside reverse transcriptase inhibitor
(NNRTI), were included. Second-line ARTwas defined
as a switch from an NNRTI-based regimen to a protease
inhibitor-based regimen, with at least oneNRTI changed.
Definitions of treatment failure
Criteria for clinical and immunologic failure were those
of the WHO [18]. Virologic failure was defined with
five alternative thresholds (125, 400, 1000, 5000 or
10 000 copies/ml). Failures had to be confirmed in a
second measurement within 1 year (usually 3 months
after the first measurement). True treatment failure was
defined as a rebound in viral load after suppression to at
least 125 copies/ml, with viral load remaining elevated
until the patient switched therapy. Whereas virologic,
immunologic and clinical failures are observations, true
treatment failure is an underlying event that cannot be
observed exactly. Detectable viral load of unknown origin
(DVU) was defined as viral load above 125 copies/ml,
which returns below 125 copies/ml while on the same
regimen. We calculated the probabilities of observing a
DVU with all five thresholds (Supplementary Table 1,
http://links.lww.com/QAD/A330).
Mathematical model
The IeDEA-SA mathematical model of ART has been
described in detail elsewhere [6]. We adapted this model
to compare quality-adjusted life-years (QALYs), costs and
cost-effectiveness between different monitoring strategies
in cohorts of patients receiving ART. In brief, the
model simulates cohorts of patients who are followed
from starting ART until death. The properties of the
individual patient and the timing of events are calculated
probabilistically on the basis of a series of rules and
parametric distributions [6]. The model was parameter-
ized with data from the South African township ART
programmes and estimates published in the literature
(Supplementary Table 2, http://links.lww.com/QAD/
A330). For the present study, we additionally modelled
viral load trajectories (Web Appendix 1, http://links.lww.
com/QAD/A330).
Each simulated patient is at a risk of true treatment
failure, clinical failure, immunologic failure and death.
The observation of the failures depends on the chosen
monitoring strategy. If viral load monitoring is available,
virologic failure is observed if the viral load trajectory isrized reproduction of this article is prohibited.
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Table 1. Patient characteristics in the Gugulethu and Khayelitsha programmes used to parameterize the mathematical model.
Unit Value
Age at baselinea (n¼9888) Years, median (IQR) 33 (29–39)
Sex (n¼9888) Number (percentage)
Male 3240 (32.8%)
Female 6648 (67.2%)
Cohort (n¼9888) Number (percentage)
Gugulethu 2658 (26.9%)
Khayelitsha 7230 (73.1%)
CD4 cell count at baselinea (n¼7259) Cells/ml; median (IQR) 93 (41–158)
HIV-1 viral load at baselinea (n¼5274) Log10 copies/ml; median (IQR) 5.0 (4.5–5.5)
First-line regimens (n¼9888) Number (percentage)
d4T 3TC EFV 4985 (50.4%)
d4T 3TC NVP 3182 (32.2%)
ZDV 3TC NVP 1031 (10.4%)
ZDV 3TC EFV 680 (6.9%)
d4T ddI EFV 7 (0.1%)
ZDV ddI EFV 3 (0.0%)
Second-line regimens (n¼353) Number (percentage)
ZDV ddI LPV/r 244 (69.1%)
ZDV 3TC EFV LPV/r 34 (9.6%)
d4T ddI LPV/r 22 (6.2%)
ZDV 3TC LPV/r 9 (2.6%)
Other 44 (12.5%)
Follow-up time on ART (n¼9888) Months, median (IQR) 17.8 (7.5–29.8)
Time from ART start to switch to second line (n¼353) Months, median (IQR) 21.2 (13.7–30.3)
A total of 9888 patients were followed for 16 278 person-years on first-line therapy and 435 person-years on second-line therapy. 3TC, lamivudine;
d4T, stavudine; ddI, didanosine; EFV, efavirenz; IQR, interquartile range; LPV/r, ritonavir-boosted lopinavir; NVP, nevirapine; ZDV, zidovudine.
aBaseline variables were defined as the closest value within 3 months before up to 2 weeks after antiretroviral therapy initiation.above the limit of detection (LOD) at the time of the
measurement. Virologic failure may also be observed if
the trajectory is below the LOD but DVU is present,
typically due to blips [19,20] or nonadherence. After an
immunologic or virologic failure is observed, another
measurement is taken 3 months later. If failure is
observed again, the patient switches to second-line
ART. On second-line ART, the patient continues to be
at risk of failure. Finally, the number of expected HIV
transmissions is calculated. Each patient is assigned
a frequency of partner change and sex acts. The times
of virologic failures and switching determine the value of
the viral load at each sex act. The expected number of
new infections is calculated using a relationship between
viral load and infectiousness based on the results of the
Rakai study in Uganda [21,22] (Web Appendix 2, http://
links.lww.com/QAD/A330).
Costs, quality-adjusted life-years and
incremental cost-effectiveness ratios
Costs of appointments, CD4 and viral load measurements
and ART were considered (Supplementary Table 3,
http://links.lww.com/QAD/A330). Cost estimates
of the antiretroviral drugs were based on the ceiling
price list of the Clinton Health Access Initiative
(CHAI) [23]. We used the average of the two most
common first-line (zidovudine/lamivudine/nevirapine
or tenofovir/lamivudine/efavirenz, $146.50/year) and
second-line (zidovudine/lamivudine/ritonavir-boosted
lopinavir or tenofovir/lamivudine/ritonavir-boosted lopi-
navir, $465.50/year) regimens. On the basis of discussionsCopyright © Lippincott Williams & Wilkins. Unautwith experts and organizations developing and imple-
menting POC-VL tests, a range of prices per test was
assumed. With the currently available laboratory-based
VL tests, the cost of the consumables is about US$28
and the cost of the machine between US$100 000 and
US$225 000 [13]. The cost-effectiveness study [24] of the
Ugandan trial [5] estimated the total cost per test to be
US$29.64, but higher estimates have also been reported
[25,26]. TheBill &MelindaGates Foundation is currently
funding the development of a qualitative POC-VL test
costing US$3–US$5 per cartridge and less than US$1000
per machine [14]. We assumed that a plausible minimum
for the unit cost of the POC-VL test (including
consumables and per-test costs of the machine) would
be US$5 with an LOD of 1000 copies/ml or higher. For
lower thresholds, we assumed a minimum of US$10 per
test. Finally, we assumed that the cost would not exceed
US$20 per test for any LOD.
Quality of life weights were derived from the disability
weights according to the Global Burden of Disease
project [27]. For asymptomatic HIV, the weight was
0.865. For symptomatic HIV, we took the weight
of the most common disease, tuberculosis (TB), and
multiplied it with the weight of asymptomatic HIV:
0.8650.729¼ 0.631. We used the same weights for all
patients irrespective of age. We also estimated costs
and lost QALYs in the partners infected by the modelled
patients. We assumed that the infected partners would
have a life expectancy of 40 years at the time of infection,
which would be reduced to 30 years because of HIV.horized reproduction of this article is prohibited.
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(ICERs), which are defined as the ratio of the change
in costs divided by the change in QALYs. Both QALYs
and costs were discounted by 3% per year.
Model scenarios
The following monitoring strategies were modelled:
clinical monitoring, 6-monthly CD4 cell count monitor-
ing and 6-monthly viral load monitoring with a
qualitative POC-VL test with an LOD of 125, 400,
1000, 5000 or 10 000 copies/ml. We assumed that the
results of the viral load test would be immediately
available to the caregiver and the patient. We used the
model to calculate the ICERs of viral load monitoring
with different LODs compared with either CD4 cell
count or clinical monitoring. We investigated three
possible benefits of routine viral load monitoring: in
Scenario A, we included only the more accurate
detection of treatment failure and more timely and
potentially more appropriate switching of patients
to second-line ART. In Scenario B, we additionally
considered the effect on HIV transmission. In Scenario C,
we also assumed that the risk of virologic failure is twice as
high with clinical or CD4 cell count monitoring than
with viral load monitoring, because viral load monitoring
detects nonadherence and improves adherence by making
targeted interventions possible [28,29].Results
We present key model outcomes, including the number of
unnecessary switches to second-line ART, the number of
missed true treatment failures, the QALYs expected at the
start of ART, the costs of patient management on ART (in
total and broken down by costs of appointments, tests and
ART) and outcomes related to HIV transmission (QALYs
lost due to new infections and total costs due to new infec-
tions). These outcomes are given in Table 2 per lifetime of
onepatient or 100 patients onART, bymonitoring strategy
and the five different LODs for the POC-VL test.
Five to six out of 100 true treatment failures remained
unobserved over the entire lifetime with viral load
monitoring strategies, compared with 37 with CD4
and 76 with clinical monitoring. The number of un-
necessary switches to second-line ART per 100 patients
was nine with clinical monitoring and five with CD4 cell
count monitoring. With viral load monitoring, it ranged
from 15 (lowest LOD, 125 copies/ml) to 5 or fewer
(LODs 1000 copies/ml). Despite these differences in
the accuracy of monitoring and switching, only small
differences in the quality-adjusted life expectancy
emerged, with mean QALYs expected at the start of
ART ranging from 12.78 with clinical monitoring
to 12.93 with POC-VL monitoring. Expressed per
100 patients, the difference in QALYs was 15. If wepyright © Lippincott Williams & Wilkins. Unauthoassumed that the true treatment failure rate was twice as
high with clinical monitoring compared with viral load
monitoring (Scenario C), this difference increased to
33 QALYs. Depending on the monitoring strategy, the
number of new HIV infections ranged from around four
with POC-VL monitoring to seven per 100 patients with
clinical monitoring, leading to a loss of 15–23QALYs per
100 patients (Table 2). The number of new infections was
higher in viral load monitoring with LOD 125 copies/ml
compared with higher LODs. This is due to the large
number of unnecessary switches to second-line ART,
which will move second-line failure forward in time and,
in the absence of further treatment options, increase the
total number of patients on failing regimens.
Total (lifetime) cost of ART ranged between US$3037
per patient (clinical monitoring) and US$4739 per
patient (viral load monitoring, US$20/VL test, LOD
125 copies/ml). The most important determinant of
total costs was second-line ART, which increased over
three-fold from US$456 per patient (clinical monitoring)
to US$1506 per patient (viral load monitoring,
LOD 125 copies/ml) (Fig. 1). The costs of tests were
substantially higher in strategies with viral load monitor-
ing than CD4 cell count monitoring even when assuming
a low unit cost of US$5 per viral load test. New HIV
infections caused additional costs betweenUS$9400 (viral
load monitoring, LOD 1000 or 5000 copies/ml) and
US$14500 (clinical monitoring) per 100 patients on ART
(Table 2) but were not an important contributor to costs
over the lifetime of the index patients on ART (Fig. 1).
As viral load monitoring using an LOD of 125 or
400 copies/ml was more expensive, did not improve
survival and caused slightly more transmissions than viral
load monitoring with a higher LOD, these two strategies
were excluded from the cost-effectiveness analyses.
The cost-effectiveness of POC-VLmonitoring compared
with CD4 cell count monitoring was poor in Scenario A
(Table 3): even the most cost-effective viral load
monitoring scenario (US$5 per POC-VL test, LOD
10000 copies/ml) had an ICER of US$5960 per QALY.
Compared with clinical monitoring, CD4 cell count
monitoring (ICER US$3300/QALY) was more cost-
effective than viral load monitoring (ICERUS$4010 per
QALY) under the same assumptions (US$5/test, LOD
10000 copies/ml). Including the effect on transmission
(Scenario B) improved the cost-effectiveness of routine
viral load monitoring. Compared with CD4 cell count
monitoring, the ICER of routine viral load monitoring
with the same assumptions as above decreased from
US$5960 under Scenario A to US$2230 per QALY.
Compared with clinical monitoring, POC-VL monitor-
ing became more cost-effective than CD4 cell count
monitoring (US$2450/QALY versus US$2590/QALY).
Finally, in Scenario C, routine POC-VL monitoring
became a clearly cost-effective strategy. Compared with
CD4 cell count monitoring, viral load monitoring wasrized reproduction of this article is prohibited.
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Fig. 1. Breakdown of costs of antiretroviral therapy care per patient in different monitoring strategies. Unit cost of viral load test
was assumed to be US$10. ART, antiretroviral therapy.cost-saving if the cost of the viral load test was US$5. The
ICER compared with either CD4 cell count or clinical
monitoring remained belowUS$2500 per QALYwith all
LODs and costs of POC-VL tests.
Figure 2 shows the cost-effectiveness of POC-VL
monitoring compared with CD4 cell count monitoring
(left panel) and clinical monitoring (right panel) forpyright © Lippincott Williams & Wilkins. Unautho
Table 3. Cost-effectiveness of point-of-care routine viral load monitoring
Unit cost of viral
load test (US$)
Scenario A
Compared with CD4 monitoring 5
10
20
Compared with clinical monitoring 5
10
20
Scenario B
Compared with CD4 monitoring 5
10
20
Compared with clinical monitoring 5
10
20
Scenario C
Compared with CD4 monitoring 5
10
20
Compared with clinical monitoring 5
10
20
Cost-effectiveness is presented as incremental cost-effectiveness ratio (U
effectiveness of CD4 versus clinical monitoring is also shown. Scenario A
(equal failure rates, HIV transmission considered) and Scenario C (true treat
load monitoring, HIV transmission considered). c/s, cost-saving; LOD, limScenarios A, B and C. The LOD was 1000 copies/ml and
the costs of POC-VL tests and of second-line ARTranged
fromUS$5 toUS$50 andUS$150 toUS$500, respectively.
The limits for cost-effectiveness (three times per-capita
gross domestic product) are shown for three sub-Saharan
African countries: Zambia (US$4242/QALY), Mozam-
bique (US$1749/QALY) and Malawi (US$1053/QALY)
[30]. In Scenarios A and B, the cost-effectiveness ofrized reproduction of this article is prohibited.
compared with CD4 or clinical monitoring in three scenarios.
CD4 monitoring
POC viral load monitoring
LOD (copies/ml):
1000 5000 10 000
n/a 8010 6430 5960
n/a 13 860 12 230 11 740
n/a 25 540 23 830 23 340
3300 4560 4140 4010
3300 6120 5690 5550
3300 9230 8780 8650
n/a 3010 2340 2230
n/a 5470 4780 4740
n/a 10 380 9670 9790
2590 2760 2490 2450
2590 3790 3500 3470
2590 5830 5530 5520
n/a c/s c/s c/s
n/a 760 520 460
n/a 2460 2210 2170
2540 1110 990 960
2540 1570 1440 1420
2540 2500 2360 2340
S$/quality adjusted life year) with 3% annual discounting. Cost-
(equal failure rates, HIV transmission not considered), Scenario B
ment failure rate twice as high with CD4 or clinical compared to viral
it of detection; n/a, not applicable; POC, point-of-care.
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Fig. 2. Cost-effectiveness of point-of-care routine viral load monitoring compared with CD4 (left panel) or clinical monitoring
(right panel) as a function of the unit cost of a viral load test and the annual costs of second-line antiretroviral therapy in three
scenarios: A (equal failure rates, no transmission), B (equal failure rates, transmission included) andC (failure rate two times higher
with clinical or CD4 monitoring compared with viral load monitoring, transmission included). Limit of detection of the viral load
test was assumed to be 1000 copies/ml. The black lines show the maximum limit of cost-effectiveness (three times per-capita gross
domestic product) for selected southern African countries. ART, antiretroviral therapy; QALY, quality-adjusted life-year.routine viral load monitoring was highly sensitive to the
cost of second-line therapy: the lower the cost of the
second-line therapy, the more cost-effective viral load
monitoring was. In Scenario C, the cost of the POC-VL
test was themost important determinant when comparing
with CD4 cell count monitoring, whereas the cost of
second-line ARTwas again the determining factor in the
comparison with clinical monitoring (Fig. 2).
In Scenario A, viral load monitoring could be considered
cost-effective in Zambia if both viral load and second-line
costs were minimised. In Scenario B, cost-effectiveness in
Mozambique could be reached under the same conditions.
The pattern changed in Scenario C when viral load
monitoring was compared with CD4 cell count monitor-
ing: as viral load monitoring now decreased the need for
second-line therapy, cost-effectiveness increased with
higher second-line therapy costs. Assuming a fixed price
ofUS$500 per year for second-line therapy (corresponding
to current levels), a unit cost of US$12 per viral load test
would render viral load monitoring cost-effective in
Malawi. A unit cost of US$5 would be cost-saving.Discussion
This mathematical modelling study found that POC-VL
monitoring likely not only improves survival slightly andCopyright © Lippincott Williams & Wilkins. Unautprevents new HIV infections but also increases the costs of
ART. Viral load monitoring more accurately detects
treatment failure, but as the risk of failure is low, the
resulting benefit on survival was small. The cost-
effectiveness was thus poor when, in Scenario A, we only
considered this benefit of POC-VLmonitoring.Whenwe
also included effects on adherence and HIV transmission,
our estimates of cost-effectiveness improved. Nevertheless,
POC-VL monitoring remained more expensive than
CD4 cell count monitoring even when reducing the
costs of POC tests to US$5, as in most scenarios, viral
load monitoring increased the need for second-line
ART and required additional tests to confirm failure.
To minimize unnecessary switches to second-line ART,
the LOD of the POC-VL test should be 1000 copies/ml
or higher.
We studied the cost-effectiveness of POC-VL monitor-
ing under a range of assumptions, with results covering
a wide range of ICERs from cost-saving to over
US$25000/QALY saved. We did not highlight any
particular scenario, as the key determinants, that is the
unit cost of the POC-VL test and the overall benefit of
viral load monitoring, remain unknown. The assumed
benefits in Scenarios B and Cwill also vary across different
settings. In particular, the effect on HIV transmission
will depend on the sexual behaviour, and the effect
on adherence on the type of adherence intervention in
place in a given programme.horized reproduction of this article is prohibited.
Co
1490 AIDS 2013, Vol 27 No 9Our study consistently supports the use of viral load tests
with detection limits of 1000 copies/ml or above. This is
at odds with current practice: a systematic review found
that out of 39 studies from sub-Saharan Africa reporting
a single virologic failure threshold, only two used
10 000 copies/ml as recommended by WHO at that
time [31], and 12 used a threshold of 500 copies/ml or
below [32]. Since then, WHO reduced the threshold
from 10 000 to 5000 copies/ml [18]. Using a threshold
below 1000 copies/ml is problematic because it results in
a large number of DVUs. Additional measurements are
required to determine whether a detectable viral load has
returned to undetectable levels before switching to
second-line ART. Moreover, some patients will have two
consecutive DVUs and therefore switch to second-line
therapy unnecessarily.
The cost-effectiveness of routine viral load compared
with CD4 cell count monitoring has been investigated in
several modelling studies [25,26,33–37] as well as a RCT
[5] (Supplementary Table 4, http://links.lww.com/
QAD/A330). The results from these studies vary and
are difficult to compare because monitoring frequency,
failure criteria, time horizon, costs and other parameters
differed substantially between studies. Only Phillips et al.
[35] modelled adherence, and Vijayaraghavan et al. [34]
was the only study considering HIV transmission.
Moreover, our study, together with the recent analysis
by Hamers et al. [26], were the only two studies that
replaced viral load monitoring with CD4 cell count
monitoring, rather than combining them. The results of
Hamers et al. [26] were clearly in favour of viral load
monitoring: the ICER was $86 per life-year when
compared with CD4 cell count monitoring. However,
Hamers et al. [26] investigated a laboratory-based,
quantitative viral load test and assumed 100% sensitivity
and specificity. We found that the poor specificity with
low LODs led to many unnecessary switches. We feel that
a specificity of 100% is unrealistic even with a quantitative
test, and that the high cost-effectiveness reported by
Hamers et al. [26] is questionable.
Our study has several limitations. The lack of empirical
data on the effect of viral load monitoring on adherence
and consequently the rate of virologic failure is one of
them. In the Khayelitsha and Gugulethu township
cohorts less than 5% of all patients failed virologically
in the first year of ART. We assumed that without viral
load monitoring, failure rates would be twice as high.
Some support for a higher rate of virologic failure in the
absence of viral load monitoring comes from cross-
sectional studies of virologic failure from settings without
routine viral load monitoring. For example, in the
HIV/AIDS outpatient clinic of the Central Hospital in
Yaounde´, Cameroon, the percentage of patients with
detectable viral load at 1 year was 16% [38]. Similarly, 26%
of individuals receiving ART in Luanda, Angola, had
detectable viral load after a median of 1 year of follow-uppyright © Lippincott Williams & Wilkins. Unautho[39]. In a rural district of Malawi, 13% of patients on ART
had detectable viral load at 10 months [40]. In all three
studies, virologic failure was defined as a viral load above
1000 copies/ml. However, the key question – to what
extent routine viral load monitoring prevents treatment
failure – remains unanswered. More research is urgently
needed to address this question.
Another limitation is the lack of data on long-term
outcomes: simulations were not limited to a fixed
time window, but modelled costs and benefits over the
entire lifespan. We thus had to extrapolate the progression
of the disease from the available data, which was restricted
to, at most, 10 years of follow-up. Our results may
therefore be sensitive to long-term outcomes, although
their influence on model outcomes was reduced by
annual discounting. Also, the data on disease progression
from the two township ART programmes in Cape Town,
which have electronic medical records and access to
routine viral load and CD4 cell count monitoring and
second-line ART, may not be applicable to other settings
in sub-Saharan Africa. We did not explicitly model
all potential benefits of POC-VL testing, for example
improved retention in care [41] or the prevention of viral
resistance. The effect on adherence was modelled by
varying virologic failure rates, but costs of adherence
interventions were not included. Finally, our estimates of
new infections do not take into account transmission
dynamics at the population level or differences in risk
behaviours. We will expand the present model to address
these shortcomings.
Conclusion
Our study demonstrates that the impact of POC-VL
monitoring on adherence and HIV transmission remains
poorly understood despite the fact that these are the key
factors that determine whether or not POC-VL tests will
be cost-effective. To minimize unnecessary switches,
the detection limit of the test should not be less than
1000 copies/ml, which has important implications for the
design of these tests. In general, lowering the cost of any
POC-VL test, and of second-line ART regimens, are the
most promising strategies to maximize cost-effectiveness
of monitoring ARTwith POC-VL tests.Acknowledgements
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